Mantle cell lymphoma (MCL) is frequently diagnosed at advanced stages and is characterized by multiple extranodal sites of disease, most notably the bone marrow, peripheral blood, and gastrointestinal tract. Historically the prognosis of mantle cell lymphoma has been poor with median survival of four...
FDA Approves Liso-Cel for Relapsed/Refractory Mantle Cell Lymphoma The FDA approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) treated with at least 2 prior lines of systemic therapy including a Bruton...
A few case reports of lymphoma presenting in this manner have been documented. We report a case of relapsed mantle cell lymphoma (MCL) presenting as a Sister Mary Joseph's nodule. Although the few reports of lymphoma exhibiting umbilical metastasis suggest that patients may still expect a ...
High-dose chemo-radio- immunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99:3158-3162.Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmu- notherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. ...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-ce
Introduction: Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult‐to‐treat population with poor outcome, where no standard therapy exists. There is a paucity of large‐scale data in relapsed or refractory (r/r) MCL. Methods: MANTLE‐FIRST, an ...
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587–593. Article CAS Google Scholar Singhal S...
John P. Leonard, MD:Now we have very recent data with the approval of acalabrutinib, a new Bruton's tyrosine kinase inhibitor for mantle cell lymphoma. We had some updated data presented here at this meeting. I think that there are some similarities between ibrutinib and acalabrutinib, and...
Background Limited data are available on the clinical activity of venetoclax (ven) in mantle cell lymphoma (MCL). In 2 small retrospective studies of patients (pts) with MCL previously treated with BTK inhibitors (BTKi), ven resulted in overall response rates (ORRs) of 50-53% and median ...
The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance. The primary endpoint was investigator-assessed overall response r